News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
856,808 Results
Type
Article (87152)
Company Profile (704)
Press Release (768931)
Multimedia
Podcasts (160)
Webinars (24)
Section
Business (232946)
Career Advice (4136)
Deals (39776)
Drug Delivery (132)
Drug Development (91174)
Employer Resources (200)
FDA (18236)
Job Trends (17382)
News (397119)
Policy (39877)
Tag
Academia (3002)
Academic (2)
Accelerated approval (16)
Adcomms (33)
Allergies (111)
Alliances (56979)
ALS (130)
Alzheimer's disease (1633)
Antibody-drug conjugate (ADC) (199)
Approvals (18221)
Artificial intelligence (439)
Autoimmune disease (40)
Automation (22)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (22)
Biosimilars (145)
Biotechnology (482)
Bladder cancer (111)
Brain cancer (45)
Breast cancer (425)
Cancer (3396)
Cardiovascular disease (289)
Career advice (3548)
Career pathing (34)
CAR-T (224)
CDC (43)
Cell therapy (614)
Cervical cancer (28)
Clinical research (74741)
Collaboration (1225)
Company closure (4)
Compensation (809)
Complete response letters (45)
COVID-19 (2929)
CRISPR (72)
C-suite (451)
Cystic fibrosis (128)
Data (3501)
Decentralized trials (2)
Denatured (57)
Depression (89)
Diabetes (399)
Diagnostics (7026)
Digital health (28)
Diversity (10)
Diversity, equity & inclusion (49)
Drug discovery (203)
Drug pricing (168)
Drug shortages (36)
Duchenne muscular dystrophy (175)
Earnings (98607)
Editorial (52)
Employer branding (25)
Employer resources (169)
Events (132107)
Executive appointments (942)
FDA (20384)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (11)
Funding (1089)
Gene editing (156)
Generative AI (43)
Gene therapy (484)
GLP-1 (980)
Government (5330)
Grass and pollen (7)
Guidances (329)
Healthcare (20933)
HIV (47)
Huntington's disease (32)
IgA nephropathy (50)
Immunology and inflammation (202)
Immuno-oncology (17)
Indications (44)
Infectious disease (3140)
Inflammatory bowel disease (175)
Inflation Reduction Act (13)
Influenza (84)
Intellectual property (150)
Interviews (814)
IPO (17916)
IRA (59)
Job creations (5195)
Job search strategy (2863)
Kidney cancer (15)
Labor market (66)
Layoffs (617)
Leadership (30)
Legal (10143)
Liver cancer (88)
Longevity (12)
Lung cancer (476)
Lymphoma (243)
Machine learning (17)
Management (65)
Manufacturing (527)
MASH (114)
Medical device (14801)
Medtech (14815)
Mergers & acquisitions (22652)
Metabolic disorders (1032)
Multiple sclerosis (109)
NASH (23)
Neurodegenerative disease (174)
Neuropsychiatric disorders (49)
Neuroscience (2479)
NextGen: Class of 2025 (7687)
Non-profit (5094)
Now hiring (54)
Obesity (522)
Opinion (300)
Ovarian cancer (110)
Pain (141)
Pancreatic cancer (139)
Parkinson's disease (210)
Partnered (27)
Patents (368)
Patient recruitment (235)
Peanut (55)
People (65946)
Pharmaceutical (143)
Pharmacy benefit managers (25)
Phase I (23046)
Phase II (32448)
Phase III (24440)
Pipeline (2352)
Policy (273)
Postmarket research (3554)
Preclinical (10403)
Press Release (72)
Prostate cancer (165)
Psychedelics (48)
Radiopharmaceuticals (280)
Rare diseases (581)
Real estate (7405)
Recruiting (76)
Regulatory (27555)
Reports (64)
Research institute (2669)
Resumes & cover letters (650)
Rett syndrome (11)
RNA editing (14)
RSV (62)
Schizophrenia (113)
Series A (180)
Series B (131)
Service/supplier (30)
Sickle cell disease (74)
Special edition (24)
Spinal muscular atrophy (168)
Sponsored (38)
Startups (4313)
State (2)
Stomach cancer (17)
Supply chain (90)
Tariffs (81)
The Weekly (101)
Vaccines (985)
Venture capital (63)
Weight loss (359)
Women's health (54)
Worklife (20)
Date
Today (53)
Last 7 days (514)
Last 30 days (2629)
Last 365 days (34083)
2025 (22347)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1278)
Alabama (75)
Alaska (7)
Arizona (290)
Arkansas (14)
Asia (50733)
Australia (8909)
California (8613)
Canada (2626)
China (807)
Colorado (365)
Connecticut (385)
Delaware (235)
Europe (116469)
Florida (1282)
Georgia (295)
Hawaii (3)
Idaho (67)
Illinois (776)
India (43)
Indiana (419)
Iowa (19)
Japan (256)
Kansas (121)
Kentucky (35)
Louisiana (20)
Maine (75)
Maryland (1190)
Massachusetts (6533)
Michigan (290)
Minnesota (529)
Mississippi (4)
Missouri (111)
Montana (32)
Nebraska (26)
Nevada (96)
New Hampshire (75)
New Jersey (2384)
New Mexico (31)
New York (2358)
North Carolina (1327)
North Dakota (10)
Northern California (3809)
Ohio (273)
Oklahoma (17)
Oregon (49)
Pennsylvania (1819)
Puerto Rico (18)
Rhode Island (42)
South America (1654)
South Carolina (43)
South Dakota (1)
Southern California (3244)
Tennessee (138)
Texas (1347)
United States (32151)
Utah (256)
Virginia (234)
Washington D.C. (82)
Washington State (740)
West Virginia (4)
Wisconsin (90)
There are 856,808 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact
Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug conjugates and T cell engagers for autoimmune diseases and gentler conditioning for sickle cell/beta thalassemia gene-editing therapy Casgevy.
September 2, 2025
·
2 min read
·
Heather McKenzie
Cancer
Servier Commits up to $530M Into Eye Cancer Deal With IDEAYA
The French giant is gaining access to darovasertib, a small molecule protein kinase C inhibitor already in Phase II/III trials, with rights for the whole world besides the U.S.
September 2, 2025
·
2 min read
·
Dan Samorodnitsky
Deals
Arrowhead Nabs up to $2B Novartis Commitment for siRNA Parkinson’s Program
Novartis is licensing ARO-SNCA, a preclinical siRNA therapy for synucleinopathies, a group of neurodegenerative disorders including Parkinson’s disease.
September 2, 2025
·
1 min read
·
Annalee Armstrong
Inflammatory bowel disease
Roche Makes Preclinical IBD Play in $420M+ OMass Pact
The OMass partnership will boost Roche’s strategy in inflammatory bowel diseases, currently led by afimkibart, an anti-TL1A therapy the pharma obtained from its $7.1 billion acquisition of Telavant in 2023.
September 2, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Novo’s Wegovy Cuts Cardio Risk by 57% Versus Tirzepatide
Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis approval last month and prime position in the oral obesity race.
September 2, 2025
·
2 min read
·
Tristan Manalac
Approvals
Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi
While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction regimen next year, its financial impact remains “uncertain,” as potentially higher revenues from the injection could be offset by steeper costs of production, according to Jefferies.
September 2, 2025
·
2 min read
·
Tristan Manalac
Obesity
Lilly Ends Two Mid-Stage Trials for Second Obesity Asset
While Eli Lilly’s orforglipron is full speed ahead for a regulatory filing this year, the pharma is also pushing forward with one more Phase II study of naperiglipron, which uses the same scaffold as Pfizer’s failed obesity drugs danuglipron and lotiglipron.
September 2, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
September 2, 2025
·
18 min read
Press Releases
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
September 2, 2025
·
4 min read
Press Releases
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
September 2, 2025
·
8 min read
1 of 85,681
Next
